DR ANTHONY MELVIN CRASTO,WorldDrugTracker, helping millions, A 90 % paralysed man in action for you, I am suffering from transverse mylitis and bound to a wheel chair,With death on the horizon, This will not stop me, Gods call only..........
DR ANTHONY MELVIN CRASTO Ph.D ( ICT, Mumbai) , INDIA 29Yrs Exp. in the feld of Organic Chemistry,Working for GLENMARK PHARMA at Navi Mumbai, INDIA. Serving chemists around the world. Helping them with websites on Chemistry.Million hits on google, world acclamation from industry, academia, drug authorities for websites, blogs and educational contributio
n

Saturday, 10 October 2015

Iwona Wrona Receives Novartis Fellowship in Organic Chemistry for Women and Minorities

 

Dr. Iwona Wrona Ph. D. 2009
iwona.wrona@cubist.com
Iwona joined the Panek group in 2004.

 https://www.linkedin.com/pub/iwona-wrona/6/b8b/745

 

Summary

Project Leader with seven years of pharmaceutical experience in pain and antibacterial therapeutic areas. Key member of a team that delivered an IND candidate and co-inventor of two development candidates that have progressed to pre-clinical studies. Highly motivated team leader who supervised, coached and developed a multidisciplinary team of scientists. Expertise in organic chemistry, medicinal chemistry, analog synthesis/design, experiment troubleshooting, hit to lead- triage, lead optimization and project leadership.

Experience



Scientist II

Cubist Pharmaceuticals
(3 years 3 months)Lexington, MA
Project Leader, TRPA1
• Analyzed HTS data for validation and follow up, resulting in two novel hit to lead series
• Advanced one series to LO stage affording several compounds with promising efficacy in animal models
• Effectively managed team of up to 12 chemists (including external CRO FTEs) and line-managed two direct reports, resulting in high level of productivity and quality
• Worked across disciplines to identify key project issues and to define and implement chemistry plan
• Co-inventor of TRPA1 development candidate drug that has progressed into pre-clinical studies
(Open)1 honor or award
(Open)3 courses


Scientist I

Cubist Pharmaceuticals
(2 years 11 months)Lexington, MA
Transient Receptor Potential Ankyrin 1 (TRPA1) Project
• Chemistry lead for TRPA1 program managing a team of up to 5 chemists
• Designed and synthesized molecules in collaboration with Hydra Biosciences, Inc. resulting in advancement of CB-625 into Phase I clinical trials
• Designer, contributor/executor of the pro-drug scale up campaign to improve solubility of the Xanthine series, resulting in two pre-development candidates
Thiopeptide Program
• Designed and synthesized semi-synthetic thiopetide analogs to improve solubility
• Identified multiple entry points for rapid SAR development
(Open)1 honor or award
(Open)2 courses


Senior Scientist

Schering-Plough Research Institute
(9 months)Cambridge, MA
• Designed and synthesized small molecule inhibitors of mTOR kinase for treatment of cancer

 

 

 

 

 

Education


Boston University

Doctor of Philosophy (Ph.D.), Organic Chemistry

Adviser: Professor James S. Panek
Dissertation:
I. Total Synthesis and Biological Evaluation of Reblastatin, Autolytimycin and Related Structural Derivatives
II. Synthesis and Biological Evaluation of Stereochemical Analogs of Bistramide A
(Open)2 honors and awards

College of the Holy Cross

BA, Chemistry, Cum Laude



Ms. Sujata Bardhan (2004/2005 Novartis Fellow), Prof. John Porco, and Ms. Iwona Wrona (2005/2006 Novartis Fellow)


....
.



Iwona Wrona is a fourth year graduate student in James Panek’s laboratory.  She graduated with a B.A. in chemistry (cum laude) from the College of the Holy Cross, Worcester, MA (2002), and she received her M.S. in Chemistry from Boston University (2004).  Iwona is working on the total synthesis of reblastatin.
Her publications include:

Wrona, I. E.; Gabarda, A. E.; Evano, G.; Panek, J. S. “Total Synthesis of Reblastatin”, J . Am. Chem. Soc. 2005, 127, 15026.
Herrick, R. S.; Wrona, I.; McMicken, N.; Jones, G.; Ziegler, C.; Shaw, J. “Preparation and Characterization of Rhenium(I) Compounds with Amino Ester Derivatized Diimine Ligands. Investigations of Luminescence. Crystal Structures of Re(CO)3Cl(pyca-β-Ala-OEt) and Re(CO)3Cl(pyca-L-Asp(OMe)-OMe)”, J. Organometallic Chemistry 2004, 689,4848.
Herrick, R. S.; Ziegler, C. J.; Bohan, H.; Corey, M.; Eskander, M.; Giguere, J.;
McMicken, N.; Wrona, I. E. “Preparation and Characterization of Molybdenum andTungsten Compounds with Diazabutadiene Ligands Constructed from Amino Esters and Glyoxal. Crystal Structures of meso and C2-symmetric isomers of Mo(CO)4(dabasp(OMe)-OMe”, J. Organometallic Chemistry 2003, 687, 178.




Publications



Metal-Catalyzed Synthesis of Hetero-Substituted Alkenes and Alkynes

Tetrahedron
2014




Synthesis of Reblastatin, Autolytimycin and Non-Benzoquinone Analogues: Potent Inhibitors of Heat Shock Protein 90

Journal of Organic Chemistry
2010



Synthesis of a 35-Member Stereoisomer Library of Bistramide A: Evaluation of Effects on Actin State, Cell Cycle and Tumor Cell Growth

Journal of Organic Chemistry
2009



Total Synthesis of Reblastatin

Journal of American Chemical Society
2005

Patents



Preparation of 2,6-dioxo-7H-purine-7-actamide derivatives as TRPA1 inhibitors

United States WO 2014113671
Issued January 17, 2014




Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitors and their preparation and use in the treatment of diseases

United States WO 2010118207
Issued April 8, 2010


 


 Map of lexington ma

 
 
 ////////

No comments:

Post a Comment